UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Blood, 2018-06, Vol.131 (24), p.2661-2669

2018

Volltextzugriff (PDF)

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Clinical cancer research, 2019-01, Vol.25 (1), p.90-98

2019

Volltextzugriff (PDF)

Pediatric Cancer Therapeutics Development

1, 2022

Volltextzugriff (PDF)

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA

Experimental hematology, 2021-06, Vol.98, p.47-52.e6

2021

Volltextzugriff (PDF)

Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia

Cancer cell, 2008-06, Vol.13 (6), p.483-495

2008

Volltextzugriff (PDF)

PB1889: KB‐LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3‐MUTATED R/R AML

HemaSphere, 2023-08, Vol.7 (S3), p.e1492994-n/a

2023

Volltextzugriff (PDF)

MLL rearrangements in haematological malignancies: lessons from clinical and biological studies

British journal of haematology, 1999-09, Vol.106 (3), p.614-626

1999

Volltextzugriff (PDF)

The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10

Blood, 2002-05, Vol.99 (10), p.3780-3785

2002

Volltextzugriff (PDF)

Future Directions

Pediatric Cancer Therapeutics Development, 2022, p.177-181

2022

Volltextzugriff (PDF)

Targeted Small Molecule Drug Discovery

Pediatric Cancer Therapeutics Development, 2022, p.9-24

2022

Volltextzugriff (PDF)

Exploratory Clinical Development: From First in Humans to Phase 3 Ready

Pediatric Cancer Therapeutics Development, 2022, p.41-49

2022

Volltextzugriff (PDF)

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL

Blood, 2000-12, Vol.96 (12), p.3887-3893

2000

Volltextzugriff (PDF)

The TALE Homeodomain Protein Pbx2 Is Not Essential for Development and Long-Term Survival

Molecular and Cellular Biology, 2004-06, Vol.24 (12), p.5324-5331

2004

Volltextzugriff (PDF)

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

Blood, 2022-11, Vol.140 (Supplement 1), p.5932-5933

2022

Volltextzugriff (PDF)

The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver

Blood, 2001-08, Vol.98 (3), p.618-626

2001

Volltextzugriff (PDF)

Responses in patients with AML and treated with entospletinib monotherapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19010-e19010

2023

Volltextzugriff (PDF)

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome

Proceedings of the National Academy of Sciences - PNAS, 2019-01, Vol.116 (2), p.695-700

2019

Volltextzugriff (PDF)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia

Blood, 2021-11, Vol.138, p.1282-1282

2021

Volltextzugriff (PDF)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1282-1282

2021

Volltextzugriff (PDF)

Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-08-05

2022

Volltextzugriff (PDF)

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Blood, 2021-11, Vol.138 (Supplement 1), p.3356-3356

2021

Volltextzugriff (PDF)

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Blood, 2022-11, Vol.140 (Supplement 1), p.3377-3378

2022

Volltextzugriff (PDF)

Abstract 4956: Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4956-4956

2018

Volltextzugriff (PDF)

CpG island methylator phenotype and childhood leukemia

Clinical cancer research, 2006-08, Vol.12 (16), p.4787-4789

2006

Volltextzugriff (PDF)

Abstract 5469: Dexamethasone interrupts paclitaxel-induced apoptosis in solid tumor cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5469-5469

2015

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(72)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(16)
Humans
(12)
Animals
(8)
Mice
(8)
Biological And Medical Sciences
(7)
Hematology
(7)
Oncology
(7)
Female
(5)
Hematologic And Hematopoietic Diseases
(5)
Histone-Lysine N-Methyltransferase
(5)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(5)
Medical Sciences
(5)
Cancer
(4)
Dna-Binding Proteins - Genetics
(4)
Male
(4)
Oncogene Proteins, Fusion - Genetics
(4)
Phenotype
(4)
Aged
(3)
Cell Biology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Pediatric Cancer Therapeutics Development

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA

Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia

PB1889: KB‐LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3‐MUTATED R/R AML

MLL rearrangements in haematological malignancies: lessons from clinical and biological studies

The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10

Future Directions

Targeted Small Molecule Drug Discovery

Exploratory Clinical Development: From First in Humans to Phase 3 Ready

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL

The TALE Homeodomain Protein Pbx2 Is Not Essential for Development and Long-Term Survival

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver

Responses in patients with AML and treated with entospletinib monotherapy

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Abstract 4956: Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model

CpG island methylator phenotype and childhood leukemia

Abstract 5469: Dexamethasone interrupts paclitaxel-induced apoptosis in solid tumor cells

Suchergebnisse filtern